Teva Launches Generic Seroquel on First Day of Patent Loss (TEVA, AZN)

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
We noted earlier today that AstraZeneca plc (NYSE: AZN) had lost a patent ruling and that the company’s anti-pyschotic drug Seroquel lost its patent protection today. That’s all it took for Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) to kick out its quetiapine generic for Seroquel.

Teva’s price sheet shows the difference a patent makes in the UK. An equal supply of 100-mg coated tablets of Seroquel costs about $180 compared with the generic cost of about $27. In its announcement, Teva notes that it has released 10 new products in 11 weeks, and 7 of those came on the first day of patent expiration.

Teva’s announcement is available here.

The company’s share price is up about 1.5% at $43.72 in a 52-week range of $35.00-$51.30.

Contact [email protected] for any questions or corrections.

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

HPE Vol: 26,431,700
NCLH Vol: 17,600,839
LRCX Vol: 12,118,424
IVZ Vol: 4,557,369
AMD
AMD Vol: 26,902,257

Top Losing Stocks

CTRA Vol: 73,319,495
APA
APA Vol: 4,400,255
PSKY Vol: 18,873,941
COST Vol: 4,545,300
CINF Vol: 2,196,176